Actively Recruiting
Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma
Led by Insight Eyecare Specialties, Inc. dba Vision Source Eyecare, · Updated on 2025-11-18
35
Participants Needed
1
Research Sites
82 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To evaluate the effect of brimonidine tartrate 0.025% on conjunctival hyperemia in patients treated with netarsudil 0.02%/latanoprost 0.005% mono-therapy for intraocular pressure lowering.
CONDITIONS
Official Title
Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients 18-65 years old diagnosed with open-angle glaucoma or ocular hypertension
- Currently on netarsudil 0.02%/latanoprost 0.005% monotherapy for 2-6 weeks or more
- Able to switch from current glaucoma treatment to netarsudil 0.02%/latanoprost 0.005% for at least 4 weeks before Visit 3
- Experience conjunctival redness graded at least 2 on the Efron scale after 4 weeks or more on netarsudil/latanoprost
- Best corrected visual acuity of 20/30 or better in the study eye
- Willing and able to self-administer or have help to use the study drug
- Willing and able to follow study procedures and attend follow-up visits
You will not qualify if you...
- Allergy or hypersensitivity to brimonidine, netarsudil, latanoprost, or components of these eye drops
- Use of any other topical eye medications
- Active eye infection, inflammation unrelated to glaucoma, uveitis, iritis, or congenital aphakia
- Conditions affecting redness grading such as pterygium, pinguecula, chemosis, episcleritis, or scleritis
- Moderate or severe dry eyes
- Pregnant, planning pregnancy, or breastfeeding
- Use of other vasoconstrictive eye drops in the past 90 days (other than brimonidine 0.025%)
- Previous incision surgery to lower eye pressure
- Previous laser or microinvasive glaucoma surgery within 6 months
- Intraocular or per-ocular surgery within the past 3 months
- Advanced glaucoma or cup-to-disc ratio over 0.8
- Non-responsive to netarsudil 0.02%/latanoprost 0.005%
- Significant systemic or eye diseases affecting study outcomes as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Vision Source
Kansas City, Missouri, United States, 64111
Actively Recruiting
Research Team
C
Crystal Remington Optometrist, OD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here